Skip to main content

Circulating tumor cells for tailoring BMP targeted therapies

Objective

Gastro-intestinal (GI) cancers, including gastro-esophageal junctional (GEJC), gastric (GC), colorectal (CRC) and pancreatic cancer (PC) are devastating malignancies that annually affect over 2 million persons worldwide and lead to more than 600,000 deaths (Globocan 2012). Given the current trends, the incidence of GI cancer is expected to increase further. Conventional therapies include chemo- and radiation therapy combined with surgery. However, amongst cancer patients, GI cancer patients have one of the poorest outcomes with a 5-year survival ranging from only 60% for CRC to a mere 5% for PC
At the moment, important steps are being taken to implement the highly specific anti-BMP4 low molecular weight antibodies (Dwarfbodies ®; DB, recently developed by us) in the clinic as a novel treatment strategy for gastro-intestinal (GI) cancers. To enable optimal treatment a diagnostic compendium is required. The CTC4BMP project aims to deliver a blood based method for patient stratification to identify patients that will benefit from the BMP4 inhibiting Dwarfbody therapy.

Host institution

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Net EU contribution
€ 150 000,00
Address
Meibergdreef 15
1105AZ Amsterdam
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Beneficiaries (1)

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
Net EU contribution
€ 150 000,00
Address
Meibergdreef 15
1105AZ Amsterdam

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00